The trial will involve both single and multiple-ascending doses of SUDO-550 being given to healthy volunteers.

InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe plaque psoriasis.

Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 ...